CMVLF News and Press, Cellectis Romainville Ord From 10/07/25

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that findings highlighting...

2025-08-05 11:50:31 ET Cellectis S.A. (CLLS) Q2 2025 Earnings Conference Call August 05, 2025 08:00 AM ET Company Participants Adrian Kilcoyne - Chief Medical Officer Andre Choulika - Co-Founder, CEO & Director Arthur Stril - CFO & Chief Business Officer ...

Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financi...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...

2025-06-05 09:44:48 ET More on Cellectis, Cibus Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave Cellectis Non-GAAP EPS of -$0.17, revenue of $12M ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annua...

2025-05-12 17:08:54 ET More on Cellectis Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cellectis Historical earnings data for Cellectis Financial information for Cellectis Read the full article on Seek...

Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 AstraZeneca partnersh...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financia...